Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T
Sponsor: American Gene Technologies International Inc.
Summary
Long-term follow-up of study subjects who received AGT103-T product in HIV study. The AGT103-T is genetically modified cells that resist infection with HIV causing a depletion of HIV in HIV-infected study participants.
Official title: A Long-Term Follow-Up Study of Participants Treated With the Lentiviral-Based Genetically Modified, Autologous Cell Product, AGT103-T
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
7
Start Date
2022-08-29
Completion Date
2038-09-29
Last Updated
2022-12-02
Healthy Volunteers
No
Conditions
Interventions
Gene modified therapy
No investigational cell product will be administered
Locations (2)
Georgetown University
Washington D.C., District of Columbia, United States
Washington Health Institute
Washington D.C., District of Columbia, United States